Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Mustang Bio, Inc.

Mustang Bio, Inc. (“Mustang”) is a clinical-stage bio-pharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang has partnered with top medical institutions to advance the development of CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID.

California Institute for Regenerative Medicine

California Institute of Regenerative Medicine (CIRM)

National Institutes of Health

Runway Growth Capital

Horizon Technology Finance

Mustang Bio

Mustang Bio announces its expansion into #autoimmunediseases with MB-106, a CD20-targeted, 3rd-generation autologous CAR T-cell therapy. A Phase 1 trial is expected to initiate in the fourth quarter of this year to demonstrate clinical proof-of-concept. $MBIO Learn more here: https://bit.ly/4azqUGS

Mustang Bio reports full-year 2023 financial results and recent corporate highlights. $MBIO Read more here: https://bit.ly/3Vdj7Kk

Phase 1 clinical data were published in @NatureMedicine that demonstrated the promising safety and clinical activity of Mustang Bio’s MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of patients with recurrent and refractory malignant glioma, including #glioblastoma. $MBIO Learn more here:  https://bit.ly/3TeNAVQ


#DYK one out every 10 Americans is living with a rare disease? This #RareDiseaseDay, learn more about Mustang's pipeline and its treatments for rare diseases. https://bit.ly/3Ij0flf #XSCID #BubbleBoyDisease #WaldenstromMacroglobulinemia #GBM $MBIO 


#DYK Waldenstrom Macroglobulinemia (WM) is a rare #bloodcancer that originates from malignant B-cells and there is no FDA-approved therapy or standard of care in the third-line setting? There are about 1,400 new patients per year in the U.S. who are diagnosed with the disease. 
 
This #RareDiseaseDay, learn more about #WM and Mustang Bio’s ongoing MB-106 Phase 1/2 trial here: https://bit.ly/49Ku9KW #CD20-targetedCAR T-cell #WaldenstromMacroglobulinemia $MBIO 

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-12.65M -	-31.29M 147.26%	-30.66M 2.00%	-46.39M 51.29%	-60.02M 29.37%	-66.37M 10.59%	-77.53M 16.81%	-51.60M 33.44%
depreciation and amortization		2K -	630K 31,400%	1.37M 117.14%	1.78M 30.48%	2.31M 29.19%	3.03M 31.44%	2.23M 26.59%
deferred income tax								-125K -
stock based compensation		2.01M -	4.96M 146.52%	2.66M 46.29%	2.99M 12.12%	3.31M 10.75%	2.28M 30.99%	568K 75.12%
change in working capital	663K -	597K 9.95%	2.47M 313.40%	132K 94.65%	3.09M 2,243.18%	-637K 120.59%	4.03M 732.65%	-2.98M 173.85%
accounts receivables				-19K -	4K 121.05%	-35K 975%	14K 140%	-3.58M 25,671.43%
inventory				19K -	-4K 121.05%	35K 975%	-14K 140%
accounts payables	668K -	1.33M 99.40%	2.47M 85.44%	296K 88.02%	3.15M 964.53%	-175K 105.55%	5.30M 3,128.57%	125K 97.64%
other working capital	-5K -	-735K 14,600%	-2K 99.73%	-164K 8,100%	-58K 64.63%	-462K 696.55%	-1.27M 174.89%	479K 137.72%
other non cash items	7.86M -	15.73M 100.06%	3.36M 78.64%	8.64M 157.26%	14.83M 71.58%	7.73M 47.91%	3.12M 59.68%	2.43M 21.86%
net cash provided by operating activities	-4.13M -	-12.95M 213.59%	-19.24M 48.63%	-33.58M 74.50%	-37.32M 11.13%	-53.67M 43.81%	-65.07M 21.24%	-49.48M 23.96%
investments in property plant and equipment		-2.80M -	-7.95M 183.85%	-3.69M 53.49%	-4.41M 19.40%	-5.37M 21.62%	-3.08M 42.62%	-114K 96.30%
acquisitions net		-2.38M -	1.07M 145.26%				127K -	6M 4,624.41%
purchases of investments		-46.00M -	-52.50M 14.13%
sales maturities of investments		20M -	61.00M 205.01%	17.60M 71.14%
other investing activites		2.12M -	-1.07M 150.61%
net cash used for investing activites		-29.05M -	557K 101.92%	13.91M 2,397.13%	-4.41M 131.72%	-5.37M 21.62%	-2.95M 44.99%	5.89M 299.39%
debt repayment	-5.60M -	-320K 94.29%		-13.61M -	-15.75M 15.75%		-27.35M -	-30.38M 11.06%
common stock issued	35.01M -	50.30M 43.67%		54.14M -	97.03M 79.23%	71.92M 25.88%	6.62M 90.79%	4.29M 35.18%
common stock repurchased		1.68M -						923K -
dividends paid		-320K -						-477K -
other financing activites	2.22M -	-1.36M 161.32%	181K 113.29%	24.58M 13,481.77%	-3.16M 112.87%	-1.07M 66.11%	54.78M 5,210.35%	-445K 100.81%
net cash used provided by financing activities	31.63M -	49.98M 58.01%	181K 99.64%	65.12M 35,875.69%	78.12M 19.97%	70.85M 9.31%	34.06M 51.93%	-26.08M 176.58%
effect of forex changes on cash								-1K -
net change in cash	27.50M -	7.98M 71.00%	-18.51M 332.02%	45.44M 345.56%	36.39M 19.92%	11.81M 67.54%	-33.96M 387.47%	-69.42M 104.41%
cash at beginning of period		27.50M -	35.48M 29.00%	16.97M 52.17%	62.41M 267.81%	98.80M 58.31%	110.62M 11.96%	75.66M 31.61%
cash at end of period	27.50M -	35.48M 29.00%	16.97M 52.17%	62.41M 267.81%	98.80M 58.31%	110.62M 11.96%	76.66M 30.70%	6.23M 91.87%
operating cash flow	-4.13M -	-12.95M 213.59%	-19.24M 48.63%	-33.58M 74.50%	-37.32M 11.13%	-53.67M 43.81%	-65.07M 21.24%	-49.48M 23.96%
capital expenditure		-2.80M -	-7.95M 183.85%	-3.69M 53.49%	-4.41M 19.40%	-5.37M 21.62%	-3.08M 42.62%	-114K 96.30%
free cash flow	-4.13M -	-15.75M 281.38%	-27.19M 72.66%	-37.28M 37.10%	-41.73M 11.95%	-59.03M 41.46%	-68.14M 15.44%	-49.59M 27.23%

NASDAQ:MBIO

Mustang Bio

Last Close

0.35

26/07 20:00

Market Cap

15.08M

Beta: 1.86

Volume Today

1.12M

Avg: 49.10K

PE Ratio

−0.16

PFCF: −0.23

Preview